Search clinical trials for: delstrigo

Total 15 results

ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
University Hospital, Caen
Merck Sharp & Dohme LLC

Not yet recruiting

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (DOR)

Hiv

France
Professor Francois Venter
Merck Sharp & Dohme LLC; Africa Health Research Institute

Recruiting

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (Opti-DOR)

HIV-1-infection

South Africa
University of Liverpool
Liverpool School of Tropical Medicine; Desmond Tutu Health Foundation

Recruiting

Doravirine Dose Optimisation in Pregnancy (DoraDO)

HIV

South Africa
Chelsea and Westminster NHS Foundation Trust
Merck Sharp & Dohme LLC

Recruiting

The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients (META-D)

Hiv

United Kingdom
Thomas Benfield

Recruiting

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil (AVERTAS-2)

HIV Infections | Obesity | Renal Insufficiency | Osteoporosis | Hiv | Weight Gain | HIV Lipodystrophy

Denmark
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
University Health Network, Toronto
Merck Canada Inc.

Terminated

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF? (DeLiTE)

Hiv | Weight Gain

Canada
Institut de Médecine et d'Epidémiologie Appliquée...
Merck Sharp & Dohme LLC

Active, not recruiting

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" (DORASPEP)

HIV Infections

France
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

HIV-1 Infection
Professor Francois Venter

Completed

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (DORA)

HIV-1-infection

South Africa
Thomas Jefferson University

Completed

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women (IDENTIFY)

Gender Dysphoria | Transgender Women | Transgender Health | Human Immunodeficiency Virus

United States
Prism Health North Texas
Merck Sharp & Dohme LLC

Withdrawn

Doravirine and Weight Gain in Antiretroviral Naive (DAWN)

Obesity | Metabolic Syndrome | Body Weight Changes | Human Immunodeficiency Virus | Fasting | Minority Health | ART | BMD

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) (DRIVE BEYOND)

HIV-1 Infection
David Garcia Cinca
Dr. Josep Mallolas

Unknown

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (DORAVIPEP)

Hiv

Spain, France

3

Subscribe